Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily
H. S. Jhajj, J. S. Schardt, N. Khalasawi, E. L. Yao, T. S. Lwo, N.-Y. Kwon, R. L. O'Meara, A. A. Desai, P. M. Tessier
Abstract
Agonist antibodies that activate cellular receptors are being pursued for therapeutic applications ranging from neurodegenerative diseases to cancer. For the tumor necrosis factor (TNF) receptor superfamily, higher-order clustering of three or more receptors is key to their potent activation. This can be achieved using antibodies that recognize two unique epitopes on the same receptor and mediate receptor superclustering. However, identifying compatible pairs of antibodies to generate biepitopic antibodies (also known as biparatopic antibodies) for activating TNF receptors typically requires animal immunization and is a laborious and unpredictable process. Here, we report a simple method for systematically identifying biepitopic antibodies that potently activate TNF receptors without the need for additional animal immunization. Our approach uses off-the-shelf, receptor-specific IgG antibodies, which lack intrinsic (Fc-gamma receptor-independent) agonist activity, to first block their corresponding epitopes. Next, we perform selections for single-chain antibodies from human nonimmune libraries that bind accessible epitopes on the same ectodomains using yeast surface display and fluorescence-activated cell sorting. The selected single-chain antibodies are finally fused to the light chains of IgGs to generate human tetravalent antibodies that engage two different receptor epitopes and mediate potent receptor activation. We highlight the broad utility of this approach by converting several existing clinical-stage antibodies against TNF receptors, including ivuxolimab and pogalizumab against OX40 and utomilumab against CD137, into biepitopic antibodies with highly potent agonist activity. We expect that this widely accessible methodology can be used to systematically generate biepitopic antibodies for activating other receptors in the TNF receptor superfamily and many other receptors whose activation is dependent on strong receptor clustering.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by epitope selection
H. Akiba, J. Fujita, … K. Tsumoto·bioRxiv·Dec 15, 2022
- Conversion of an agonistic anti-TNFR2 biparatopic antibody into an antagonist by insertion of peptide linkers into the hinge region
Takuya Otsuki, Shigeyuki Matsumoto, … Hiroki Akiba·Journal of Biological ChemistryPeer-reviewed·Jul 31, 2025
- Bispecific Antibody Architecture and TNFRSF Target Selection Determine CD8+ T Cell Differentiation and Anti-tumour Immunity
Marcus A. Widdess, Lucy Wilkinson, … Aymen Al‐Shamkhani·bioRxiv·Jun 24, 2026
- A bispecific antibody targeting a membrane-proximal ASGPR1 region promotes TNF-α recruitment and uptake
- De novo masking domains that gate TNF-family ligand assembly and activity
Shota Kudo, Brian A. Kuhlman·bioRxiv·Apr 22, 2026
- The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors
Obinna C. Ubah, Eric W. Lake, … Caroline Jane Barelle·Nature CommunicationsPeer-reviewed·Nov 29, 2025